Biovica International AB (BIOVIC.B)

Overview

Biovica International AB (publ) stands out as a prominent biotech entity rooted in Uppsala, Sweden, with its establishment dating back to 2008. This innovative company dedicates its efforts to developing and commercializing ground-breaking blood-based biomarker assays, which play a pivotal role in enhancing the monitoring and prediction of cancer therapies, not only within Sweden but on an international scale as well. With a primary focus on breast cancer, Biovica International AB (publ) showcases its commitment to advancing cancer treatment and care, benefiting both the medical community and patients across the globe.

Products and Services

• DiviTum TKa

At the forefront of Biovica International AB (publ)'s product lineup is the DiviTum TKa, a pioneering biomarker assay known for its remarkable ability to measure thymidine kinase activity. This biomarker stands as a reflection of tumor cell proliferation, providing invaluable insights that aid in the accurate monitoring and assessment of cancer therapies. Specifically designed with a focus on breast cancer, DiviTum TKa serves a critical role in the advancement of personalized medicine, offering key benefits to cancer institutes, pharmaceutical companies, and collaborative groups looking to enhance treatment outcomes and patient care.